Long-term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review
Annals of Internal Medicine
Fink, Howard A.MacDonald, RoderickForte, Mary L.Rosebush, Christina E.Ensrud, Kristine E.Schousboe, John T.Nelson, Victoria A.Ullman, KristenButler, MaryOlson, Carin M.Taylor, Brent C.Brasure, MichelleWilt, Timothy J.
Long-term alendronate and zoledronic acid therapies reduce fracture risk in women with osteoporosis. Long-term bisphosphonate treatment may increase risk for rare adverse events, and continuing treatment beyond 3 to 5 years may reduce risk for vertebral fractures. Long-term hormone therapy reduces hip fracture risks but has serious harms.
Copyright to this work is held by the author(s), in accordance with United States copyright law (USC 17). Readers of this work have certain rights as defined by the law, including but not limited to fair use (17 USC 107 et seq.). Questions regarding copyright and use issues should be directed to the publishers or rights holders of each individual work. Questions regarding this collection may be directed to the Northwestern Health Sciences University Greenawalt Library at 952-885-5419 or at email@example.com.
American College of Physicians